Fit for Health 2.0

Support to SMEs & Researchers in FP7 and Horizon 2020 health-oriented projects

Related European programmes

www.fitforhealth.eu

20.05.2015 | Bucharest - Romania

Dr Cristina Pascual | National Documentation Centre - EKT

Fit for Health is funded by the European Commission

SEVENTH FRAMEWORK PROGRAMME

- Innovative Medicines Initiative - IMI-2
- European & Developing Countries Clinical Trials Partnership - EDCTP2
- Ambient Assisted Living Joint Programme - AAL JP-2
- Joint Programming Initiatives in Health sector
- European Innovation Partnership in Active & Healthy Ageing (EIP AHA)
- COST Programme

Innovative Medicines Initiative – IMI

Fit for Health 2.0

- Public-Private Partnership between EU & the European Federation of Pharmaceutical Industries & Associations
- Funding collaborative research in the PHARMA area
  - Development of new therapies (vaccines, medicines & treatments of unmet need)
  - Biological markers
  - Tools to improve drug development process
- Competitive calls with pre-defined topics
- Addressed to: universities, research organisations, SMEs, industry, patients' organisations, hospitals, regulatory agencies & authorities

http://www.imi.europa.eu

www.imi-partnering.eu (Partner search tool)

Innovative Medicines Initiative - IMI

- Collaborative research projects funding via combined contributions from
  - Public funds goes exclusively to academia, public organizations, SMEs, patients associations, …
  - Private – as 'in kind' contributions from the participating pharmaceutical companies
- Average project size 20 million €
- Average partnership 10-15 pharmaceutical companies & 10-15 academia, SME, regulatory, patient organizations

IMI 2 Call 5 expected top be launched **summer 2015**
Indicative text at http://www.imi.europa.eu/content/future-topics

European & Developing Countries Clinical Trials Partnership - EDCTP2

- Public-Public Partnership between EU & member states & Sub-Saharan African states
- Funding collaborative research in the area: clinical development of new interventions for poverty related diseases
  - Clinical trials (RIAs)
  - Training & mobility actions (individual fellowships)
  - Capacity building for clinical trials in Africa (CSAs)
- Competitive calls with broad topics
- Addressed to: universities, research organisations, NGOs, SMEs, industry, hospitals, patients organisations

http://www.edctp.org/

http://www.edctp.org/funding-opportunities/calls/#

Ambient Assisted Living Joint Programme – AAL JP

- Public - Public partnership between EC & 22 countries (19 MS & 3 AC)
- Funding close-to-market, demand-driven collaborative research, in the area of ICT for ageing well
- Competitive calls with pre-defined topics
- Addressed to: universities, research organisations, industry, SMEs and end-users
- Average size of AAL consortium: 3 to 10 partners (at least 3 partners from 3 different AAL Partner States, including 1 SME & 1 business partner & 1 end-user)

http://www.aal-europe.eu/

Joint Programming Initiatives - JPIs

- Coordination of national research efforts to tackle common social problems in a more effective & efficient way
  - "Neurodegenerative Diseases Research" http://www.neurodegenerationresearch.eu /
  - "More years, better lives" http://www.jp-demographic.eu/
  - "Antimicrobial Resistance" http://www.jpiamr.eu/
  - "A healthy diet for a healthy life" https://www.healthydietforhealthylife.eu
- JPIs launch transnational calls for research collaborative projects with pre-defined topics
- Addressed to: universities, research organisations, NGOs & Industry & SMEs (depending on JPI)

Information on open calls at NETWATCH
http://netwatch.jrc.ec.europa.eu/web/ni/network-information/joint-calls
Does your country/region participate in?



European Innovation Partnership on Active & Healthy Ageing – EIP AHA

- EIP AHA is a cooperation of EU, regions, industry, research institutions and healthcare professionals:
  - Challenge-driven: Active & Health ageing (AHA)
  - Focusing on EU societal benefits &
  - Modernisation & competitiveness of the EU market in AHA
- EIP AHA is **not a funding instrument**, but for coordination with broader Research & Innovation policies & programmes:
  - Topics in SC1 Work Programme & AAL JP programme

http://ec.europa.eu/active-healthy-ageing

European Cooperation in Science & Technology- COST Programme

- Funding of international networks of national funded basic to pre-competitive research:
  - Connect scientists with policy-makers, governmental & regulatory bodies, industry, spin-offs
  - Bridging research communities: precursor of advanced multidisciplinary research
- Continuous open calls (2 cut-off dates) with no pre-defined topics funding coordination & networking activities
- Address to: Universities, research institutes, NGOs & Industry, SMEs

http://www.cost.eu/

COST Funded Action in the HEALTH Sector

Targeted Radionuclide Therapy: curing tumours while avoiding damage of healthy organs

Ionizing radiation has been utilised for many years to kill cancer cells. Did you know that most methods currently used to deliver radiation to a tumour can give unacceptably high radiation doses to surrounding normal tissues?

The risk of radiation damage to vital structures often limits the amount of radiation that can be used to treat patients. In order to avoid damage to normal organs and maximise the effect of radiation on the tumour, several approaches are being investigated to deliver radiation only where needed. One successful approach deals with concentrating radioactivity specifically on cancer cells. This can be achieved by coupling suitable radionuclides to antibodies, antibody fragments or small peptides that bind cell surface receptors or other proteins specifically overexpressed by cancer cells. Such radiopharmaceuticals are being intensively studied and developed.

Fit for Health 2.0

EKT

ΕΘΝΙΚΟ ΚΕΝΤΡΟ ΤΕΚΜΗΡΙΩΣΗΣ

NATIONAL DOCUMENTATION CENTRE

Thank you!

Dr Cristina Pascual | EKT

cpascual@ekt.gr | **www.ekt.gr**